Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
Purpose
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.
Condition
- Long COVID
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- English speaking - Diagnosis of Long COVID
Exclusion Criteria
- Any history of: - Coronary artery dissection or aortic dissection - Neurological disease (e.g. dementia, Alzheimer's disease, or other brain-related disease) - Cerebrovascular disease or stroke - Aneurysm - If currently has: - Moderate-severe chronic obstructive pulmonary disease - Uncontrolled moderate-severe asthma - Moderate-severe bronchiectasis - Moderate-severe interstitial lung disease, requiring the use of supplemental oxygen - A necessity to use supplemental oxygen, for any reason - New or worsening symptoms (decompensation) of heart failure - Right heart disease due to chronic pulmonary disease/sleep apnea - Uncontrolled myocardial ischemia or angina - Uncontrolled heart arrhythmias - Heart or lung infection (e.g. myocarditis or pericarditis) - Left main coronary artery stenosis - Moderate-severe aortic stenosis - Pulmonary embolism, pulmonary infarction, or other blood clots - Severe respiratory disease - Chronic kidney disease - Chronic liver disease - Females of childbearing potential will complete a urine pregnancy test at their baseline visit to rule out pregnancy - BMI >40 - Study staff unable to obtain adequate signal for cerebral blood flow
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Acute exposure: Placebo, Progressive Carbon Dioxide, Intermittent Hypoxia |
Study group will receive the three interventions in this order: Placebo, Progressive Carbon Dioxide, then Intermittent Hypoxia |
|
Experimental Acute exposure: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide |
Study group will receive the three interventions in this order: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide |
|
Experimental Acute exposure: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide |
Study group will receive the three interventions in this order: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide |
|
Experimental Acute exposure: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo |
Study group will receive the three interventions in this order: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo |
|
Experimental Acute exposure: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia |
Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia |
|
Experimental Acute exposure: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo |
Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo |
|
Placebo Comparator Placebo Group |
Study group will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days intervention period. Subjects will then return within 7 days of their final training visit to repeat baseline testing |
|
Experimental Training Group |
Training Study group will be complete 6 cycles of either progressive CO2 ramp protocol or the intermittent hypoxia protocol for 60 minutes for every visit during the 14 days. Subjects will then return within 7 days of their final training visit to repeat baseline testing |
|
Recruiting Locations
Mayo Clinic in Arizona
Scottsdale, Arizona 85259
Scottsdale, Arizona 85259
More Details
- NCT ID
- NCT06614309
- Status
- Recruiting
- Sponsor
- Mayo Clinic